Author:
Yarborough Bobbi Jo H.,Stumbo Scott P.,Janoff Shannon L.,Keast Erin M.,Leo Michael C.,Leitz Sarah J.
Reference23 articles.
1. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder, 2020 Focused Update;American Society of Addiction Medicine,2020
2. Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis;Andorn;J. Clin. Psychopharmacol.,2020
3. Continued posttrial benefits of buprenorphine extended release: RECOVER study findings;Boyett;J. Addict. Med.,2023
4. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal;Brissos;Ther. Adv. Psychopharmacol.,2014
5. Canadian Agency for Drugs and Technologies in Health, 2019. Pharmacoeconomic Review Report: Buprenorphine Extended-release Injection (Sublocade). 〈https://www.ncbi.nlm.nih.gov/books/NBK546358/pdf/Bookshelf_NBK546358.pdf〉 (Accessed 3/31/2024).